His focus is to oversee, review, and coordinate the NCI-sponsored phase III cancer treatment trials in these diseases in an effort to promote practice-changing and definitive clinical trials.

Dr. Little's research interests have focused on immune suppression-related neoplastic disease, investigation of viral targets for oncolytic therapy and immunotherapy, and antiangiogenesis.